Narmada Agrobase reported a strong 71.5% jump in Q2 FY27 revenue to Rs 20.50 crore, yet net profit slipped 44.7% to Rs 0.57 crore due to rising expenses. The company also confirmed Rs 7.70 crore from its rights issue remains in fixed deposits.
Narmada Agrobase Q2 Profit Dips Despite Significant Revenue Growth
Revenue climbed to Rs 20.50 crore (up 71.5% YoY), while net profit fell to Rs 0.57 crore (down 44.7% YoY).
Reader Takeaway: Strong revenue momentum is currently offset by sharp cost increases, impacting margins and overall bottom-line growth.
What just happened
Narmada Agrobase released its unaudited financial results for the second quarter ended September 30, 2026. While the company achieved a robust top-line expansion, jumping from Rs 11.95 crore to Rs 20.50 crore, the profitability metrics failed to keep pace. Net profit dropped to Rs 0.57 crore compared to Rs 1.03 crore in the year-ago period, largely driven by a surge in total expenses to Rs 20.00 crore from Rs 10.91 crore.
Why this matters
The divergence between revenue and profit highlights a struggle to maintain operating efficiency amidst rapid expansion. Investors are looking for signs of margin stabilization. Additionally, the company disclosed that Rs 7.70 crore raised from a rights issue remains parked in fixed deposits rather than being utilized for the intended purpose of debt repayment to the State Bank of India.
Corporate Developments
The company recently finalized a share sub-division, splitting each Rs 10 face value share into two shares of Rs 5 face value. This move is generally aimed at increasing liquidity. The company also continues to report consolidated results incorporating its wholly-owned subsidiary, Narmada Bio Feed Private Limited.
Risks to watch
The primary concern is the rising cost structure that is eating into profit margins. Furthermore, the delay in deploying rights issue funds for debt reduction may lead to ongoing interest costs that could have been mitigated.
What to track next
Watch for management commentary on the expected timeline for utilizing the remaining rights issue proceeds and any strategic plans to control input costs in the coming quarters.
